Woolston, Andrew http://orcid.org/0000-0002-6175-4805
Barber, Louise J.
Griffiths, Beatrice
Pich, Oriol
Lopez-Bigas, Nuria
Matthews, Nik
Rao, Sheela
Watkins, David
Chau, Ian
Starling, Naureen
Cunningham, David http://orcid.org/0000-0001-5158-1069
Gerlinger, Marco http://orcid.org/0000-0003-2719-299X
Article History
Received: 8 June 2020
Accepted: 20 April 2021
First Online: 20 May 2021
Competing interests
: I.C. has consultant/advisory roles with Eli-Lilly, BMS, MSD, Merck KG, Roche, Bayer and Five Prime Therapeutics. D.C. receives research funding from Amgen, Sanofi, Merrimack, Astra Zeneca, Celegene, MedImmune, Bayer, 4SC, Clovis, Eli-Lilly, Janssen and Merck KG. M.G. and N.S. receive research funding from Merck KG and BMS. The other authors declare no competing interests.